Rationale: Despite several large clinical trials assessing blood pressure lowering in acute stroke, equipoise remains particularly for ischemic stroke. The ''Blood pressure in Acute Stroke Collaboration'' commenced in the mid-1990s focussing on systematic reviews and meta-analysis of blood pressure lowering in acute stroke. From the start, Blood pressure in Acute Stroke Collaboration planned to assess safety and efficacy of blood pressure lowering in acute stroke using individual patient data.
Introduction and rationale
High blood pressure (BP) is common in both acute ischemic stroke and primary intracerebral hemorrhage and is associated independently with poor short-and long-term outcomes. 1, 2 There is general agreement on intensive lowering of elevated BP in intracerebral hemorrhage, as reflected in international guidelines based on the results of the INTERACT-2 trial; [3] [4] [5] following publication of the neutral results of the ATACH-2 trial, 6 guidelines have been further updated. Despite results of large clinical trials, [7] [8] [9] equipoise remains regarding the question of whether to treat or not to treat BP in patients with ischemic stroke. Systematic reviews of trials of BP management have been performed using published summary data and these suggest that lowering BP in the first few hours after ischemic stroke might be most effective. 10 However, such meta-analyses neither allow effects to be assessed easily in subgroups nor multiple variable analyses. In contrast, meta-analyses using individual patient data (IPD) facilitate these and are considered to be the gold-standard. 11 Additional questions also need addressing, including the management of BP before, during, and after reperfusion therapies such as intravenous thrombolysis and mechanical thrombectomy.
We detail the protocol by which the Blood Pressure in Acute Stroke Collaboration (BASC), an international collaborative IPD pooling project, will examine the results of randomized controlled trials with the intention of helping define the optimal management of BP in acute stroke.
Aims and methods

The BASC
The BASC project commenced in the mid-1990s. Early work focused on developing systematic reviews and meta-analyses based on summary (group) data and these were published in the Cochrane Database of Systematic Reviews. The first review (2001) identified randomized controlled trials specifically aiming to alter BP (BASC-1) and was followed by a wider review that included all trials involving a vasoactive drug, whether or not this was given to alter BP (BASC-2). At this stage, there were insufficient data to lead to definitive conclusions on the management of BP in acute stroke. These reviews have been updated periodically. 10, 12 It was always intended that a third phase (BASC-3) would be based on IPD, and data were shared with the collaboration through to 2003. Since then, several larger clinical trials have been published and a detailed update is now warranted. The collaborative group consists of leading international investigators of individual clinical trials.
The results will be published under the banner of BASC Collaborators, where allowed by journals. All contributing collaborators will be listed by trial in either the publication or an online appendix. The papers will be written by a Publication Committee and then distributed to all Collaborators for comment, interpretation, changes, and additions. Shared data will not be used for any purpose other than in collaboratorapproved BASC analyses.
Objectives
The overall objective of BASC is to determine the optimal management of BP in patients with acute stroke. Specific objectives are:
1. To determine the optimal management of high BP in patients with acute intracerebral hemorrhage. 2. To determine the optimal management of high BP in patients with acute ischemic stroke. 3. To assess which factors may alter the optimal management of high BP in patients with acute stroke. 4. To assess effects of different strategies (target BP, intervention classes), and continuing versus stopping pre-stroke antihypertensive therapy. 5. To assess the effect of vasoactive treatment on hemodynamic measures. 6. To assess the effect of vasoactive treatment on neuroimaging outcomes. 7. To increase understanding of the hypertensive response in acute stroke.
Eligible studies
Randomized controlled trials of BP management in acute stroke will be included involving participants with ischemic stroke and/or intracerebral hemorrhage, and covering the ultra-acute (pre-hospital), hyper-acute (<6 h), acute (<48 h) and sub-acute (<168 h) phases of stroke. Trials will be sought using electronic searches (Cochrane Library, EMBASE, PubMed, and Web of Science) and in the reference lists of published systematic reviews and ad hoc reviews. Studies that have provisional investigator agreement for inclusion in BASC-3 are listed in online Supplemental Table 1 .
Data sharing
Collaborators will be sharing data with the BASC Collaboration. Sharing will involve a formal contract between BASC and the sharing organization to ensure transparency, and pre-defined and appropriate use of data according to this BASC protocol. Data will be shared electronically, and stored on passwordprotected, encrypted hard disks in a locked room, with daily backup facilitating disaster recovery.
Baseline variables
Clinical data will include:
. Demographic: Age, sex, country of recruitment, pre-morbid modified Rankin Scale (mRS). . Medical history: Vascular risk factors. . Hemodynamic parameters: Systolic/diastolic BP, heart rate, measures of variability. . Stroke: Type (ischemic stroke, intracerebral hemorrhage, stroke mimics), severity (stroke scale), syndrome, level of consciousness (Glasgow Coma Scale). . BP treatment: Time from onset to randomization (as a surrogate for time to treatment), strategy (target BP, intervention class), route of administration.
Imaging data will be collected from trials where this is available to assess acute stroke lesion characteristics:
. Ischemic stroke: Infarct visibility, severity of attenuation change, extent, location, mass effect, intravascular thrombus, hemorrhagic transformation. . Intracerebral hemorrhage: Location, size, presence of intraventricular or subarachnoid blood.
Both: Pre-existing changes -brain atrophy, white matter lesions, prior stroke lesions.
Study outcomes Primary outcome
The primary effect variable will be functional outcome defined by the ordered distribution of the mRS at the end of trial follow-up (3 or 6 months). In the case of missing data, the last recorded score will be carried forward. Analyses will be carried out in the entire study population and then in pre-specified subgroups, as identified in Table 1 . Patients without available data, International Journal of Stroke, 13 (7) and where the above procedure for missing data cannot be applied, will be excluded from analyses. However, sensitivity analyses will use complete data based on multiple imputation where end-of-trial mRS is missing.
Secondary outcomes
The effect of BP lowering treatment on secondary outcome variables will also be studied:
Clinical parameters
. Death or dependency at the end of follow-up (mRS 3-6).
. 
Proposed stages of BASC-3
The analyses will be carried out in consecutive stages addressing specific study questions, before integrating these into a final overarching analysis. Individual statistical analysis plans for each stage will be finalized and published before data analysis. Trials for inclusion are listed in online Supplemental Table 1. 1. Nitric oxide donors in acute stroke. To assess safety and efficacy of nitric oxide donors in acute stroke. This work has been published 19 and will be updated once ongoing trials 20 have reported. 2. Continuation versus stopping pre-stroke antihypertensive therapy. To assess safety and efficacy of continuation versus stopping pre-stroke antihypertensive therapy in acute stroke. This work has been published. 21 3. Primary intracerebral hemorrhage. To assess safety and efficacy of BP lowering in patients with primary intracerebral hemorrhage. The analyses will include data from trials focussing on ICH alone, and ICH patients in trials studying a mixed population of stroke. 4. Acute IS patients receiving thrombolysis. To assess safety and efficacy of BP lowering in patients who receive thrombolysis. The analyses will include patient data from trials where thrombolysis was administered before BP lowering, where thrombolysis was administered in parallel with BP lowering, and where thrombolysis was administered after BP lowering. 5. Ischemic stroke. To assess safety and efficacy of BP lowering in patients with IS. The analyses will include data from trials focussing on IS alone, and IS patients in trials studying a mixed population of stroke. 6. All stroke. To assess safety and efficacy of BP lowering in any patient with acute stroke. The analyses will include patient data (including stroke mimic patients) from all trials of BP lowering in acute stroke. Patients with a confirmed stroke or transient ischemic attack diagnosis will then be analyzed separately.
Crosscutting neuroimaging theme. Of relevance to all of the above, questions will be assessment of baseline brain
International Journal of Stroke, 13 (7) scans (CT or MRI) and, where available, on-treatment neuroimaging. Although much work has already been published on these for individual trials, [22] [23] [24] aggregation of data will provide additional statistical power, especially in subgroups. Such analyses will be facilitated by the commonality of data collected across the trials.
Statistical analysis
A full statistical analysis plan is not given here because of the multi-phasic nature of this program of work. The analyses will be performed using the intention-to-treat dataset from each trial, as defined by each individual trial. Initial internal analyses will compare baseline and outcome data from each trial with their published results to ensure that data are complete and transferred without error. Baseline characteristics will also be compared between individual trials to identify differences in patient characteristics. Since individual trial results have already been published, results from analysis of individual trials will not be identifiable in BASC publications.
The primary effect variable (mRS) will be analyzed using ordinal logistic regression; the assumption of proportionality of odds will be tested using the likelihood ratio test. Mixed effect analyses will be performed with adjustment for key baseline variables including age, sex, pre-morbid mRS, stroke type (ischemic, hemorrhagic), stroke severity, stroke syndrome, SBP, and time from stroke onset to randomization; the source trial will be added as a random effect. For completeness, unadjusted analyses will also be performed. Analyses will be performed in key subgroups, as listed in Table 1 , with addition of an interaction term to a mixed-effects OLR model. Subgroup analyses will include tests for heterogeneity by adding an interaction term into the adjusted ordinal logistic regression model. The effect of time from onset to treatment on potential efficacy (mRS) and hazard (death) will be assessed using a multiple variable regression model, as used previously for alteplase, thrombectomy, and glyceryl trinitrate. 19, 25, 26 Since each phase of the program is likely to be analyzed only once or twice, adjustment for multiple repeat analyses, as proposed for thrombectomy, 27 will not be performed.
Secondary outcomes will be analyzed using adjusted Cox proportional hazards regression, binary logistic regression, ordinal logistic regression, or multiple linear regression, as appropriate. Multilevel models will compare BP lowering with control interventions taking into account the differences between trials. These will include the same variables listed above for covariate adjustment.
Discussion
Phase III of the BASC will use pooled IPD from completed randomized controlled trials to address the role of BP management in the acute phase of stroke. Conflicting results from multiple clinical trials indicate that BP reduction is not a straightforward question of whether to treat or not. Rather, this problem is complex and needs to take account of patient characteristics, physiological parameters including baseline BP, stroke type, timing of treatment, strategy and class of antihypertensive agent, route of administration, and dose or target BP. The question of whether or not to reduce BP in stroke has been debated for decades. Observational data have indicated consistently that acute elevation in BP is common in stroke (75% of IS and 80% of ICH), is usually present during the first 24 h, and is often self-limiting. 2 Further, high BP is a poor prognostic sign for all stroke types and subtypes.
For ICH, elevated baseline SBP is associated with hematoma expansion, 28 perihematoma edema formation, 29 and increased mortality. 30 There is increasing evidence that intensive lowering of BP reduces hematoma enlargement, 31 is safe and tolerable, does not alter cerebral blood flow, 32 and decreases rates of neurological deterioration. Current guidelines recommend lowering BP early in the course after ICH and that targeting a goal of SBP < 140 mmHg is probably safe in patients presenting with an SBP of 150 to 220 mmHg. 4, 5 Nevertheless, the neutral findings of ATACH-2 6 emphasize that re-appraisal of all published data is again required. Although guidelines recognize the need for very early treatment, none address the role of pre-hospital BP reduction.
In IS, the rationale for lowering BP is based on associations of acute high BP with early recurrence and late death and dependency. 2 It has been argued that high BP protects the brain by preserving ischemic penumbra and that antihypertensive therapy may reduce cerebral perfusion, leading to poor outcomes. Elevated BP in the setting of failed autoregulation may maintain cerebral perfusion, but comes at the cost of increased cerebral edema and hemorrhagic transformation. Clinical studies have shown mixed results, in part differentiated by drug class: while trials of angiotensin receptor antagonists, ß-receptor antagonists, and first-generation calcium channel blockers were negative, studies of enalapril and glyceryl trinitrate were neutral. 7, 33, 34 Provisional evidence suggests that glyceryl trinitrate given within 4-6 h might be beneficial, 8, 35 as is being tested prospectively. 20 Hence, whether to lower BP per se may not be the relevant question in IS; rather, it may be what is the appropriate agent and timing in which to do so, and can this be done without compromising cerebral blood flow. Furthermore, the influence of patient characteristics that are present prior to the ICH or IS on BP lowering
International Journal of Stroke, 13 (7) interventions is unknown, although these same variables are known to worsen long-term recovery after both ICH and IS. These include having a prior stroke, white matter lesions or brain atrophy.
The BASC is an ongoing international collaborative project that will curate and analyze IPD from a wide variety of clinical trials to address the core questions related to acute BP reduction in stroke. The collaboration is open to all randomized controlled trials in which subjects were randomized to BP treatment versus control in the acute phase of stroke.
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